Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
Flere episoder fra "Kidney360"



Gå ikke glip af nogen episoder af “Kidney360” - abonnér på podcasten med gratisapp GetPodcast.








